deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT03496545

Efficacy of Bromocriptine For Fever Reduction in Acute Neurologic Injury (BFF)

Efficacy of Bromocriptine to Reduce Body Temperature in Febrile Critically-ill Adults With Acute Neurologic Disease: an Open-label, Blinded Endpoint, Randomized Controlled Trial

Sponsor: University of California, San Francisco

Conditions Fever Intracerebral Hemorrhage Ischemic Stroke Subarachnoid Hemorrhage Subdural Hematoma Traumatic Brain Injury
Interventions Acetaminophen 650 MG Bromocriptine 5 MG
Updated 13 times since 2018 Last updated: Jun 22, 2021 Started: Nov 30, 2018 Primary completion: Nov 2, 2019 Completion: Nov 2, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Fever and Intracerebral Hemorrhage and is currently completed. University of California, San Francisco leads this study, which shows 13 recorded versions since 2018 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Nov 2018 · 5 months · monthly snapshot~Nov 2018 – ~Jan 2019 · 2 months · monthly snapshot~Jan 2019 – ~Jun 2019 · 5 months · monthly snapshot~Jun 2019 – ~Sep 2019 · 3 months · monthly snapshot~Sep 2019 – ~Sep 2020 · 12 months · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Dec 2022 · 15 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

13 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  4. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE1_PHASE2

  5. Sep 2021 — Dec 2022 [monthly]

    Completed PHASE1_PHASE2

    Status: Active Not Recruiting → Completed

▶ Show 8 earlier versions

  1. Jan 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  2. Sep 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  3. Sep 2019 — Sep 2020 [monthly]

    Recruiting PHASE1_PHASE2

  4. Jun 2019 — Sep 2019 [monthly]

    Recruiting PHASE1_PHASE2

  5. Jan 2019 — Jun 2019 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  6. Nov 2018 — Jan 2019 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

  7. Jun 2018 — Nov 2018 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

  8. May 2018 — Jun 2018 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • University of California, San Francisco
Data source: University of California, San Francisco

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations